Bedrosian Camille L 4

What Happened
Camille L. Bedrosian, a member of Crinetics Pharmaceuticals' board of directors, was awarded equity on June 18, 2026: 5,925 restricted stock units (RSUs) and a 9,730-share derivative award (stock option-style grant). Both awards were reported at $0.00 per share (grant awards, not open-market purchases or sales).

Key Details

• Transaction date: 2026-06-18; Filing date: 2026-06-22 (filed within typical 2-business-day window).
• Awards: 5,925 RSUs (non-derivative) and 9,730 shares reported as a derivative award. Reported price: $0.00 (grant).
• Vesting: RSUs vest 100% on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders, subject to continued board service. The derivative (stock option) vests on the same schedule.
• Shares owned after the transaction: not provided in the supplied data.
• Nature of transaction: compensation/grant — not an indicator of a purchase or sale; no immediate sale or cashless exercise reported.

Context
RSUs represent the right to receive shares upon vesting; the derivative award is a stock-option-style grant that must vest before exercisability. These are routine board compensation grants and do not reflect an open-market buy or sell by the director.